Indefinite- lived intangible impairment
AbbVie Indefinite- lived intangible impairment decreased by 0.1% to $94.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.5%, from $95.28B to $94.80B. Over 5 years (FY 2020 to FY 2025), Indefinite- lived intangible impairment shows relatively stable performance with a -0.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase in impairment charges signals a decline in the value of the company's intangible assets, potentially indicating poor acquisition outcomes or changing market conditions.
Detailed definition
This represents the gross value of indefinite-lived intangible assets, excluding goodwill, that have been subject to imp...
Peer comparison
Varies significantly based on M&A history; companies with frequent acquisitions often show higher volatility in this metric.
other_intangible_assets_gross_excluding_goodwillHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $97.81B | $97.82B | $98.10B | $97.97B | $97.60B | $96.47B | $97.08B | $96.39B | $96.47B | $85.07B | $83.64B | $92.12B | $91.39B | $99.73B | $94.95B | $95.28B | $95.79B | $94.76B | $94.87B | $94.80B |
| QoQ Change | — | +0.0% | +0.3% | -0.1% | -0.4% | -1.2% | +0.6% | -0.7% | +0.1% | -11.8% | -1.7% | +10.1% | -0.8% | +9.1% | -4.8% | +0.4% | +0.5% | -1.1% | +0.1% | -0.1% |
| YoY Change | — | — | — | — | -0.2% | -1.4% | -1.0% | -1.6% | -1.2% | -11.8% | -13.9% | -4.4% | -5.3% | +17.2% | +13.5% | +3.4% | +4.8% | -5.0% | -0.1% | -0.5% |
Indefinite- lived intangible impairment at Other Companies
Frequently Asked Questions
- What is AbbVie's indefinite- lived intangible impairment?
- AbbVie (ABBV) reported indefinite- lived intangible impairment of $94.80B in Q1 2026.
- How has AbbVie's indefinite- lived intangible impairment changed year-over-year?
- AbbVie's indefinite- lived intangible impairment decreased by 0.5% year-over-year, from $95.28B to $94.80B.
- What is the long-term trend for AbbVie's indefinite- lived intangible impairment?
- Over 5 years (2020 to 2025), AbbVie's indefinite- lived intangible impairment has grown at a -0.5% compound annual growth rate (CAGR), from $97.41B to $94.87B.
- What does indefinite- lived intangible impairment mean?
- The total value of non-goodwill intangible assets that have been written down due to a loss in value.